Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Research & Development (2020 - 2025)

Historic Research & Development for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $3.9 million.

  • Insight Molecular Diagnostics' Research & Development rose 3766.42% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 2182.84%. This contributed to the annual value of $9.8 million for FY2024, which is 586.4% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Research & Development stood at $3.9 million, which was up 3766.42% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Research & Development registered a high of $5.1 million during Q1 2022, and its lowest value of $1.4 million during Q4 2022.
  • In the last 5 years, Insight Molecular Diagnostics' Research & Development had a median value of $2.5 million in 2021 and averaged $2.8 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Research & Development skyrocketed by 15505.56% in 2021, and later crashed by 6998.48% in 2022.
  • Insight Molecular Diagnostics' Research & Development (Quarter) stood at $4.6 million in 2021, then crashed by 69.98% to $1.4 million in 2022, then surged by 84.83% to $2.5 million in 2023, then dropped by 11.39% to $2.3 million in 2024, then soared by 71.82% to $3.9 million in 2025.
  • Its Research & Development was $3.9 million in Q3 2025, compared to $3.3 million in Q2 2025 and $2.9 million in Q1 2025.